Alveolus Bio
ApprovedWe are a team of scientists, clinicians, and engineers on a mission to disrupt the standard of care for chronic and infectious lung disease. Our proprietary resMIT platform delivers safe, targeted bacteria directly to the lungs to address fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation indications (NCFBE, COPD).
About
We are a team of scientists, clinicians, and engineers on a mission to disrupt the standard of care for chronic and infectious lung disease. Our proprietary resMIT platform delivers safe, targeted bacteria directly to the lungs to address fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation indications (NCFBE, COPD).
Funding History
1Total raised: $4.5M
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile